Patents by Inventor Guy Van Den Mooter
Guy Van Den Mooter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8790697Abstract: The invention provides a controlled release delivery system comprising a bio-active compound and a matrix carrier, wherein said matrix carrier is an amorphous microporous non-fibrous silicon or titanium oxide being loaded with said bio-active compound and wherein the micropores of said matrix carrier have a mean size in the range of 0.4 to 2.0 nm.Type: GrantFiled: September 9, 2005Date of Patent: July 29, 2014Assignee: K.U. Leuven Research & DevelopmentInventors: Johan Martens, Guy Van Den Mooter, Jan Van Humbeeck, Caroline Aerts, Randy Mellaerts
-
Publication number: 20130243833Abstract: A compressed formulation comprising an ordered mesoporous silica loaded with an active ingredient, a combination of microcrystalline cellulose (MCC) and croscarmellose sodium, and optional further excipients.Type: ApplicationFiled: November 28, 2011Publication date: September 19, 2013Applicant: FORMAC PHARMACEUTICALS N.V.Inventors: Monica Vialpando, Johan Martens, Guy Van Den Mooter, Filip Kiekens
-
Crystalline mesoporous oxide based materials useful for the fixation and controlled release of drugs
Patent number: 8273371Abstract: The invention describes a new class of crystalline silica material having two levels of porosity and structural order. At the first level, building units are nanoslabs of uniform size having zeolite framework. At the second structural level, nanoslabs are assembled, e.g. linked through their corners, edges or faces following patterns imposed by interaction with cationic surfactant or triblock copolymer molecules. After evacuation of these molecules, microporosity is obtained inside the nanoslabs, and a precise mesoporosity between the nanoslabs depending on the tiling pattern of the zeolite nanoslabs, as evidenced by X-ray diffraction. These materials are useful for the fixation of biologically active species, such as poorly soluble drugs.Type: GrantFiled: July 6, 2009Date of Patent: September 25, 2012Inventors: Johan Adriaan Martens, Christine Eva Antonia Kirschhock, Sebastien Philippe Brigitte Kremer, Alexander Jan Maria Herman Eugeen Aerts, Guy Van Den Mooter, Jan Van Humbeeck -
Patent number: 8258137Abstract: A process for the release of a biologically active species comprising the steps of: providing a mesoporous oxide-based material having structural order and at least one level of porosity; fixing or immobilizing said biologically active species in said ordered mesoporous oxide; and providing said ordered mesoporous oxide with said fixed or immobilized biologically active species in vivo thereby realizing intraluminally induced substantially pH-independent supersaturation of said biologically active species resulting in enhanced transepithelial transport; wherein said biologically active species is a poorly soluble therapeutic drug classified as belonging to Class II or Class IV of the Biopharmaceutical Classification System and said ordered mesoporous oxide has a pore size in the range of 4 to 14 nm.Type: GrantFiled: January 28, 2009Date of Patent: September 4, 2012Assignee: Katholieke Universiteit LeuvenInventors: Patrick Augustijns, Johan Adriaan Martens, Randy Mellaerts, Guy Van Den Mooter
-
Patent number: 8216495Abstract: A method of preparation of a solid dispersion of a polyvinyl alcohol-polyethylene glycol graft copolymer (PVA-PEG graft co-polymer), such as Kollicoat IR with a BCS Class II drug or a BCS Class IV drug, whereby the method comprises: a) dissolving the polyvinyl alcohol-polyethylene glycol graft copolymer (PVA-PEG graft co-polymer) separately in a water/first alcohol mixture; and b) dissolving the BCS Class II drug or a BCS Class IV drug, in a mixture of a second alcohol with a non alcoholic organic solvent in which the compound has an high solubility; and c) mixing the both solutions to obtain a third solution with a total amount of solved solid of 1 to 15 g per 100 ml, and optionally having an acid, including inorganic acids including hydrohalic acids, e.g.Type: GrantFiled: March 25, 2009Date of Patent: July 10, 2012Assignee: Formac Pharmaceuticals N.V.Inventors: Sandrien Janssens, Guy Van Den Mooter
-
CRYSTALLINE MESOPOROUS OXIDE BASED MATERIALS USEFUL FOR THE FIXATION AND CONTROLLED RELEASE OF DRUGS
Publication number: 20110086099Abstract: The invention describes a new class of crystalline silica material having two levels of porosity and structural order. At the first level, building units are nanoslabs of uniform size having zeolite framework. At the second structural level, nanoslabs are assembled, e.g. linked through their corners, edges or faces following patterns imposed by interaction with cationic surfactant or triblock copolymer molecules. After evacuation of these molecules, microporosity is obtained inside the nanoslabs, and a precise mesoporosity between the nanoslabs depending on the tiling pattern of the zeolite nanoslabs, as evidenced by X-ray diffraction. These materials are useful for the fixation of biologically active species, such as poorly soluble drugs.Type: ApplicationFiled: July 6, 2009Publication date: April 14, 2011Applicant: K.U. Leuven Research & DevelopmentInventors: Johan Adriaan Martens, Christine Eva Antonia Kirschhock, Sebastien Philippe Brigitte Kremer, Alexander Jan Maria Herman Eugeen Aerts, Guy Van Den Mooter, Jan Van Humbeeck -
Publication number: 20110081416Abstract: A process for preparing a 2D-hexagonal ordered mesoporous silica material with a substantially uniform pore size in the range of 4 to 30 nm comprising the steps of: preparing an aqueous solution comprising an alkali silicate solution; preparing an aqueous solution comprising a poly(alkylene oxide) triblock copolymer and a buffer with a pH greater than 2 and less than 8, adding said aqueous alkali silicate solution to said aqueous solution giving a pH greater than 2 and less than 8 and allowing a reaction between the components to take place at a temperature in the range of 10 to 100° C., and filtering off, drying and calcinating the reaction product to produce said 2D-hexagonal ordered mesoporous silica material with a substantially uniform pore size.Type: ApplicationFiled: October 15, 2010Publication date: April 7, 2011Applicant: FORMAC Pharmaceuticals N.V.Inventors: Jasper JAMMAER, Alexander Aerts, Guy Van Den Mooter, Johan Martens
-
Publication number: 20110060020Abstract: A process for the release of a biologically active species comprising the steps of: providing a mesoporous oxide-based material having structural order and at least one level of porosity; fixing or immobilizing said biologically active species in said ordered mesoporous oxide; and providing said ordered mesoporous oxide with said fixed or immobilized biologically active species in vivo thereby realizing intraluminally induced substantially pH-independent supersaturation of said biologically active species resulting in enhanced transepithelial transport; wherein said biologically active species is a poorly soluble therapeutic drug classified as belonging to Class II or Class IV of the Biopharmaceutical Classification System and said ordered mesoporous oxide has a pore size in the range of 4 to 14 nm.Type: ApplicationFiled: January 28, 2009Publication date: March 10, 2011Applicant: Katholieke Universiteit Leuven K.U. Leuven R&DInventors: Patrick AUGUSTIJNS, Johan Adriaan Martens, Randy Mellaerts, Guy Van Den Mooter
-
Publication number: 20110059175Abstract: The present invention relates generally to use of a polyvinyl alcohol-polyethylene glycol graft copolymer (PVA-PEG graft co-polymer), such as Kollicoat IR, in the formulation of solid dispersions of low aqueous solubility and dissolution rate bioactive compound and, more particularly to a system and method for improving the solubility and dissolution rate of such low aqueous solubility and dissolution rate bioactive compound, in particular the drug of low aqueous solubility, such as a BCS Class II or Class IV drug compounds.Type: ApplicationFiled: April 10, 2007Publication date: March 10, 2011Applicant: K.U.LEUVEN RESEARCH AND DEVELOPMENTInventors: Sandrien Janssens, Guy Van Den Mooter
-
Publication number: 20110018154Abstract: A method of preparation of a solid dispersion of a polyvinyl alcohol-polyethylene glycol graft copolymer (PVA-PEG graft co-polymer), such as Kollicoat IR with a BCS Class II drug or a BCS Class IV drug, whereby the method comprises: a) dissolving the polyvinyl alcohol-polyethylene glycol graft copolymer (PVA-PEG graft co-polymer) separately in a water/first alcohol mixture; and b) dissolving the BCS Class II drug or a BCS Class IV drug, in a mixture of a second alcohol with a non alcoholic organic solvent in which the compound has an high solubility; and c) mixing the both solutions to obtain a third solution with a total amount of solved solid of 1 to 15 g per 100 ml, and optionally having an acid, including inorganic acids including hydrohalic acids, e.g.Type: ApplicationFiled: March 25, 2009Publication date: January 27, 2011Applicant: FORMAC Pharmaceuticals N.V.Inventors: Sandrien Janssens, Guy Van Den Mooter
-
Crystalline mesoporous oxide based materials useful for the fixation and controlled release of drugs
Patent number: 7749521Abstract: The invention describes a new class of crystalline silica material having two levels or porosity and structural order. At the first level, building units are nanoslabs of uniform size having zeolite framework. At the second structural level, nanoslabs are assembled, e.g. linked through their corners, edges or faces following patterns imposed by interaction with cationic surfactant or triblock copolymer molecules. After evacuation of these molecules, microporosity is obtained inside the nanoslabs, and a precise mesoporosity between the nanoslabs depending on the tiling pattern of the zeolite nanoslabs, as evidenced by X-ray diffraction. These materials are useful for the fixation of biologically active species, such as poorly soluble drugs.Type: GrantFiled: June 28, 2004Date of Patent: July 6, 2010Assignee: K.U. Leuven Research & DevelopmentInventors: Johan Adriaan Martens, Christine Eva Antonia Kirschhock, Sebastien Philippe Brigitte Kremer, Alexander Jan Maria Herman Eugeen Aerts, Guy Van Den Mooter, Jan Van Humbeeck -
Patent number: 7666307Abstract: The invention provides a method for reducing the average size of biologically active compound particles or agglomerates suspended in a fluid by flowing one or more times said fluid having biologically active compound particles or agglomerates suspended therein through one or more magnetic fields to reduce the average size of a substantial portion of the biologically active compound particles or agglomerates by at least 25%. This method may be incorporated into a process for manufacturing a 10 biologically active compound formulation.Type: GrantFiled: August 25, 2004Date of Patent: February 23, 2010Assignee: K.U. Leuven Research & DevelopmentInventors: Guy Van Den Mooter, Johan Martens, Jan Nuyens
-
CRYSTALLINE MESOPOROUS OXIDE BASED MATERIALS USEFUL FOR THE FIXATION AND CONTROLLED RELEASE OF DRUGS
Publication number: 20100008990Abstract: The invention describes a new class of crystalline silica material having two levels of porosity and structural order. At the first level, building units are nanoslabs of uniform size having zeolite framework. At the second structural level, nanoslabs are assembled, e.g. linked through their corners, edges or faces following patterns imposed by interaction with cationic surfactant or triblock copolymer molecules. After evacuation of these molecules, microporosity is obtained inside the nanoslabs, and a precise mesoporosity between the nanoslabs depending on the tiling pattern of the zeolite nanoslabs, as evidenced by X-ray diffraction. These materials are useful for the fixation of biologically active species, such as poorly soluble drugs.Type: ApplicationFiled: July 6, 2009Publication date: January 14, 2010Applicant: K.U. Leuven Research & DevelopmentInventors: Johan Adriaan Martens, Christine Eva Antonia Kirschhock, Sebastien Philippe Brigitte Kremer, Alexander Jan Maria Herman Eugeen Aerts, Guy Van Den Mooter, Jan Van Humbeeck -
Publication number: 20090318519Abstract: A process for the release of a biologically active species comprising the steps of: providing a mesoporous oxide-based material having structural order and at least one level of porosity; fixing or immobilizing said biologically active species in said ordered mesoporous oxide; and providing said ordered mesoporous oxide with said fixed or immobilized biologically active species in vivo thereby realizing intraluminally induced substantially pH-independent supersaturation of said biologically active species resulting in enhanced transepithelial transport; wherein said biologically active species is a poorly soluble therapeutic drug classified as belonging to Class II or Class IV of the Biopharmaceutical Classification System and said ordered mesoporous oxide has a pore size in the range of 4 to 14 nm.Type: ApplicationFiled: January 28, 2009Publication date: December 24, 2009Applicant: Katholieke Universiteit LeuvenInventors: Patrick AUGUSTIJNS, Johan Adriaan MARTENS, Randy MELLAERTS, Guy VAN DEN MOOTER
-
Publication number: 20090311325Abstract: The present invention relates generally to use of a polyvinyl alcohol-polyethylene glycol graft copolymer (PVA-PEG graft co-polymer), such as Kollicoat IR, in the formulation of solid dispersions of low aqueous solubility and dissolution rate bioactive compound and, more particularly to a system and method for improving the solubility and dissolution rate of such low aqueous solubility and dissolution rate bioactive compound, in particular the drug of low aqueous solubility, such as a BCS Class II or Class IV drug compounds.Type: ApplicationFiled: April 10, 2007Publication date: December 17, 2009Applicant: K.U.LEUVEN RESEARCH AND DEVELOPMENTInventors: Sandrien Janssens, Guy Van Den Mooter
-
Publication number: 20090192205Abstract: A process for the release of a biologically active species comprising the steps of: providing a mesoporous oxide-based material having structural order and at least one level of porosity; fixing or immobilizing said biologically active species in said ordered mesoporous oxide; and providing said ordered mesoporous oxide with said fixed or immobilized biologically active species in vivo thereby realizing intraluminally induced substantially pH-independent supersaturation of said biologically active species resulting in enhanced transepithelial transport; wherein said biologically active species is a poorly soluble therapeutic drug classified as belonging to Class II or Class IV of the Biopharmaceutical Classification System and said ordered mesoporous oxide has a pore size in the range of 4 to 14 nm.Type: ApplicationFiled: January 28, 2009Publication date: July 30, 2009Applicant: Katholieke Universiteit Leuven K.U. Leuven R&DInventors: Patrick AUGUSTIJNS, Johan Adriaan Martens, Randy Mellaerts, Guy Van Den Mooter
-
Patent number: 7407670Abstract: Present invention provides solid dispersions comprising a poorly soluble bioactive compound dispersed in a polymer matrix characterized in that the polymer matrix comprises more than one polymer. Said solid dispersions effectively stabilize the dispersed compound while stimulating the solubilisation of the compound in an aquaeous environment.Type: GrantFiled: July 1, 2003Date of Patent: August 5, 2008Assignee: Janssen Pharmaceutica, N.V.Inventors: Karel Six, Geert Verreck, Jozef Peeters, Marcus Eli Brewster, Guy Van Den Mooter
-
Publication number: 20070275068Abstract: The invention provides a controlled release delivery system comprising a bio-active compound and a matrix carrier, wherein said matrix carrier is an amorphous microporous non-fibrous silicon or titanium oxide being loaded with said bio-active compound and wherein the micropores of said matrix carrier have a mean size in the range of 0.4 to 2.0 nm.Type: ApplicationFiled: September 9, 2005Publication date: November 29, 2007Inventors: Johan Martens, Guy Van Den Mooter, Jan Van Humbeeck, Caroline Aerts, Randy Mellaerts
-
Publication number: 20070082054Abstract: The invention provides a method for reducing the average size of biologically active compound particles or agglomerates suspended in a fluid by flowing one or more times said fluid having biologically active compound particles or agglomerates suspended therein through one or more magnetic fields to reduce the average size of a substantial portion of the biologically active compound particles or agglomerates by at least 25%. This method may be incorporated into a process for manufacturing a 10 biologically active compound formulation.Type: ApplicationFiled: August 25, 2004Publication date: April 12, 2007Inventors: Guy Van Den Mooter, Johan Martens, Jan Nuyens
-
Publication number: 20060062809Abstract: Present invention provides solid dispersions comprising a poorly soluble bioactive compound dispersed in a polymer matrix characterized in that the polymer matrix comprises more than one polymer. Said solid dispersions effectively stabilize the dispersed compound while stimulating the solubilisation of the compound in an aquaeous environment.Type: ApplicationFiled: July 1, 2003Publication date: March 23, 2006Inventors: Karel Six, Geert Verreck, Jozef Peeters, Marcus Brewster, Guy Van Den Mooter